Trebananib clinical trials
Also written AMG 386.
How each study uses trebananib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
30 studies that test it; most in 2012 (9)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 4 |
| 2008 | 1 |
| 2009 | 5 |
| 2010 | 4 |
| 2011 | 4 |
| 2012 | 9 |
| 2014 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 19 · Other 12
Amgen (18) · National Cancer Institute (NCI) (6) · Dana-Farber Cancer Institute (2) · Roswell Park Cancer Institute (1) · Gynecologic Oncology Group (1) · Takeda (1) · Austin Health (1) · University of Colorado, Denver (1)
Often tested with
Tested in the same studies.
Bevacizumab (2) · Cytarabine (1) · Sorafenib (1) · Motesanib diphosphate (1) · Sunitinib (1) · Paclitaxel (1)
Related medicines
As reviewed, each with the page that says it.
- One of Angiogenesis inhibitors source
Studies
Open first, then newest update. How each study uses trebananib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 31
- Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid TumorCompletedPhase 1Dana-Farber Cancer InstituteNCT03239145Written as TrebananibHow we know
- Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast CancerCompletedPhase 1AmgenNCT00807859Written as AMG 386 30 mg/kg, Paclitaxel and TrastuzumabHow we know
- Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid LeukemiaCompletedPhase 1Roswell Park Cancer InstituteNCT01555268Written as trebananibHow we know
- Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain TumorsCompletedPhase 2National Cancer Institute (NCI)NCT01609790Written as TrebananibHow we know
- Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney CancerCompletedPhase 2National Cancer Institute (NCI)NCT01664182Written as TrebananibHow we know
- AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With SunitinibCompletedPhase 2AmgenNCT00853372Written as TrebananibHow we know
- Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal CancerCompletedPhase 2AmgenNCT00479817Written as AMG 386How we know
- AMG 386 and Abiraterone for Advanced Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT01553188Written as AMG 386How we know
- Trebananib in Treating Patients With Persistent or Recurrent Endometrial CancerCompletedPhase 2Gynecologic Oncology GroupNCT01210222Written as TrebananibHow we know
- AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)TerminatedPhase 3AmgenNCT01281254Written as AMG386 plus PLDHow we know
- A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal FunctionCompletedPhase 1AmgenNCT01331941Written as AMG 386 + PaclitaxelHow we know
- Amgen 386 for Recurrent GlioblastomaCompletedPhase 1/2Dana-Farber Cancer InstituteNCT01290263Written as Amgen 386How we know
- TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian CancerTerminatedPhase 3AmgenNCT01493505Written as AMG 386How we know
- To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.CompletedPhase 1AmgenNCT00861419Written as AMG 386How we know
- TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube CancerCompletedPhase 3AmgenNCT01204749Written as AMG 386How we know
- Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System TumorsCompletedPhase 1National Cancer Institute (NCI)NCT01538095Written as TrebananibHow we know
- Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung CancerCompletedPhase 1/2AmgenNCT01666977Written as AMG 386How we know
- A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular CancerCompletedPhase 2AmgenNCT00872014Written as AMG 386How we know
- AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With SorafenibCompletedPhase 2AmgenNCT00467025Written as AMG 386How we know
- Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer PatientsCompletedPhase 2AmgenNCT00511459Written as AMG 386How we know
See all 31 studies that test trebananib →
Given beside what is tested · 1 — trebananib is usual care or a partner of the new treatment
Codes
What other systems call trebananib · ClinicalTrials.gg INT005678
- MeSH (NLM) C551398trebananibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) X8Y5U6NC7ETREBANANIBConfirmed FDA, NLM, Wikidata
- Wikidata Q104268400trebananibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C91711TrebananibOne source FDA
- DrugBank DB12056One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C551398 | trebananib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | X8Y5U6NC7E | TREBANANIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q104268400 | trebananib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C91711 | Trebananib | One source FDA |
| DrugBank | DB12056 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.